European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
CINCINNATI ( WXIX /Gray News) - A 7-year-old is in a hospital in Ohio fighting for her life after experiencing her second ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
Heart failure arises when the heart cannot pump blood efficiently, leading to symptoms such as shortness of breath and ...
In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...
Hope Unlimited Ministries will have its annual fundraising event featuring Point of Grace on Thursday, Oct. 17. This event ...
1d
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America ...
The RESHAPE-HF2 and MATTERHORN trials have specialists talking about whether the trials "open the door" for the treatment of ...
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In ...
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
A gran of two was forced to wait more than 25 hours in a hospital corridor after suffering a suspected heart attack. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback